Trial Profile
A feasibility study of Anthracycline-based regimen followed by Nab-Paclitaxel as adjuvant chemotherapy for breast cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2018
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Anthracyclines
- Indications Breast cancer
- Focus Therapeutic Use
- 18 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2013 New trial record